

# Genevieve M Boland

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5995249/publications.pdf](https://exaly.com/author-pdf/5995249/publications.pdf)

Version: 2024-02-01

109  
papers

11,697  
citations

70409

40  
h-index

33030

98  
g-index

440  
all docs

440  
docs citations

440  
times ranked

24121  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma. <i>JCO Precision Oncology</i> , 2024, , .	3.1	0
2	Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. <i>Journal of Clinical Oncology</i> , 2024, 42, 1169-1180.	5.4	4
3	Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. <i>Nature Immunology</i> , 2024, 25, 644-658.	13.7	9
4	Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis. <i>Nature Medicine</i> , 2024, 30, 1349-1362.	29.9	0
5	Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. <i>Nature Reviews Cancer</i> , 2024, 24, 498-512.	28.6	1
6	Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial. <i>Nature Communications</i> , 2024, 15, .	13.0	0
7	Implementation and Evaluation of an Academic Development Rotation for Surgery Residents. <i>Journal of Surgical Education</i> , 2024, 81, 1748-1755.	2.5	0
8	Incorporating Well-Being into Mentorship Meetings: A Case Demonstration at Massachusetts General Hospital Department of Surgery a Harvard Medical School Affiliate. <i>American Journal of Lifestyle Medicine</i> , 2023, 17, 213-215.	1.9	4
9	Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. <i>Nature Cancer</i> , 2023, 4, 222-239.	12.1	21
10	Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	5
11	Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Cancers</i> , 2023, 15, 2700.	3.8	1
12	Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment. <i>Nature Communications</i> , 2023, 14, .	13.0	12
13	Harnessing the Potential of Combination Immunotherapy and Oncolytic Virotherapy for Solid Tumors. <i>Annals of Surgical Oncology</i> , 2022, 29, 762-763.	1.9	1
14	PIVOT-12: a Phase III Study of Adjuvant Bempegaldesleukin Plus Nivolumab in Resected Stage III/IV Melanoma at High Risk for Recurrence. <i>Future Oncology</i> , 2022, 18, 903-913.	2.4	7
15	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	1.9	25
16	Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1147-1149.	1.2	4
17	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. <i>Cell Reports Medicine</i> , 2022, 3, 100500.	5.9	17
18	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.7	25

#	ARTICLE	IF	CITATIONS
19	STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. <i>Nature Communications</i> , 2022, 13, 1859.	13.0	21
20	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538.	35.8	86
21	MO344: Effect of Cancer Stage on Adverse Kidney Outcomes in Patients With Advanced Melanoma Treated With Immune Checkpoint Inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.8	0
22	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	3.3	21
23	Abstract 1270: Glycoproteomics-based liquid biopsy informs optimal checkpoint-inhibitor drug choice. <i>Cancer Research</i> , 2022, 82, 1270-1270.	0.9	0
24	Abstract 2030: A single-cell spatially resolved map of colorectal cancer identifies novel spatial relationships between cancer cells and the microenvironment. <i>Cancer Research</i> , 2022, 82, 2030-2030.	0.9	3
25	Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. <i>Cancer Research</i> , 2022, 82, 3610-3610.	0.9	0
26	Prediction of early-stage melanoma recurrence using clinical and histopathologic features. <i>Npj Precision Oncology</i> , 2022, 6, .	5.4	12
27	Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. <i>Nature Biotechnology</i> , 2021, 39, 451-461.	20.6	180
28	The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. <i>Cancer Discovery</i> , 2021, 11, 678-695.	14.1	135
29	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	1.9	8
30	Surgical delay and mortality for primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1089-1091.	1.2	13
31	Type 2 immunity is maintained during cancer-associated adipose tissue wasting. <i>Immunotherapy Advances</i> , 2021, 1, ltab011.	3.0	13
32	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021, 13, .	13.3	62
33	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. , 2021, 9, e002092.		10
34	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5586-5594.	7.2	200
35	Low expression of the PPAR $\gamma$ -regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases. <i>Scientific Reports</i> , 2021, 11, 7847.	3.4	14
36	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. , 2021, 9, e002292.		26

#	ARTICLE	IF	CITATIONS
37	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. <i>Oncologist</i> , 2021, 26, e1427-e1433.	4.1	11
38	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , 2021, 27, 985-992.	29.9	72
39	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. <i>Oncologist</i> , 2021, 26, 685-693.	4.1	3
40	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. <i>Nature</i> , 2021, 596, 119-125.	35.8	281
41	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5993-6000.	7.2	89
42	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021, 81, 5230-5241.	0.9	10
43	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		16
44	Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.5	29
45	Spatially organized multicellular immune hubs in human colorectal cancer. <i>Cell</i> , 2021, 184, 4734-4752.e20.	27.7	338
46	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , 2021, 12, 6023.	13.0	27
47	641â€¦Spatially organized multicellular immune hubs in MMRd and MMRp colorectal cancer. , 2021, , .		0
48	920â€¦A single-cell spatially resolved MERFISH map of the colorectal tumor immune microenvironment. , 2021, , .		2
49	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. <i>Cell</i> , 2021, 184, 6262-6280.e26.	27.7	158
50	Successful Mentor-Mentee Relationship. <i>Journal of Surgical Research</i> , 2020, 247, 332-334.	1.6	13
51	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		18
52	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. <i>Science Advances</i> , 2020, 6, .	10.8	44
53	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. <i>Nature Communications</i> , 2020, 11, 3946.	13.0	77
54	The Human and Mouse Enteric Nervous System at Single-Cell Resolution. <i>Cell</i> , 2020, 182, 1606-1622.e23.	27.7	328

#	ARTICLE	IF	CITATIONS
55	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 6039-6050.	7.2	26
56	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. <i>Nature Medicine</i> , 2020, 26, 1114-1124.	29.9	241
57	CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-Resistant Melanoma. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 26-40.	7.6	14
58	Mixed Response to Immunotherapy in Patients with Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3488-3497.	1.9	24
59	ASO Author Reflections: Mixed Response in Metastatic Melanoma Patients Treated with Immunotherapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 3498-3499.	1.9	0
60	ASO Author Reflections: Adjuvant Treatment of Melanoma in the Modern Era. <i>Annals of Surgical Oncology</i> , 2020, 27, 5137-5138.	1.9	0
61	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 757.	2.9	12
62	Targeting the cyclin-dependent kinase 5 in metastatic melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 8001-8012.	7.5	21
63	Use of immunotherapy and surgery for stage IV melanoma. <i>Cancer</i> , 2020, 126, 2614-2624.	4.1	17
64	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020, 182, 655-671.e22.	27.7	303
65	Tracking early response to immunotherapy. <i>Nature Cancer</i> , 2020, 1, 160-162.	12.1	9
66	Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 5128-5136.	1.9	13
67	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019, 20, 1231-1243.	13.7	232
68	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	165
69	The Patient Speaks: Importance of Patient Perspectives in Clinical Decision-Making. <i>Annals of Surgical Oncology</i> , 2019, 26, 2665-2666.	1.9	2
70	Oncolytic Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 419-430.	1.5	10
71	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2019, 25, 6852-6867.	7.2	85
72	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. <i>Immunity</i> , 2019, 50, 1498-1512.e5.	14.0	449

#	ARTICLE	IF	CITATIONS
73	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	4.4	44
74	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. <i>Molecular Systems Biology</i> , 2019, 15, e8323.	7.2	25
75	Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics. <i>Cell</i> , 2019, 176, 1325-1339.e22.	27.7	386
76	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. <i>Cancer Discovery</i> , 2019, 9, 396-415.	14.1	76
77	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2019, 176, 404.	27.7	197
78	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 1196-1205.	7.2	90
79	Co-targeting <i>BET</i> and <i>MEK</i> as salvage therapy for <i>MAPK</i> and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.8	83
80	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	7.2	31
81	Atypical <i>ALK</i> -positive Spitz tumors with 9p21 homozygous deletion: Report of two cases and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 136-140.	1.4	11
82	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	14.1	429
83	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 79-86.	3.3	64
84	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	14.1	532
85	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	27.7	973
86	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	27.7	1,370
87	Toward Minimal Residual Disease-Directed Therapy in Melanoma. <i>Cell</i> , 2018, 174, 843-855.e19.	27.7	552
88	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nature Medicine</i> , 2018, 24, 1545-1549.	29.9	521
89	The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. <i>Current Oncology Reports</i> , 2017, 19, 17.	4.1	34
90	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. <i>Cancer Research</i> , 2017, 77, 2318-2327.	0.9	249

#	ARTICLE	IF	CITATIONS
91	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	13.0	724
92	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , 2017, 550, 133-136.	35.8	146
93	Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2466-2468.	0.7	1
94	Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. <i>Cell Reports</i> , 2017, 21, 2796-2812.	6.3	85
95	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. <i>Oncotarget</i> , 2017, 8, 25395-25417.	1.9	68
96	Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. <i>JAMA Surgery</i> , 2016, 151, 347.	4.5	42
97	Metastatic melanoma with spontaneous complete regression of a thick primary lesion. <i>JAAD Case Reports</i> , 2016, 2, 439-441.	0.9	18
98	Principles of Melanoma Staging. <i>Cancer Treatment and Research</i> , 2016, 167, 131-148.	0.0	29
99	Melanoma: Advances in Targeted Therapy and Molecular Markers. <i>Annals of Surgical Oncology</i> , 2015, 22, 3451-3458.	1.9	15
100	The role of surgeons in building a personalized medicine program. <i>Journal of Surgical Oncology</i> , 2015, 111, 3-8.	1.7	7
101	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.7	139
102	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2015, 125, 1459-1470.	6.6	108
103	Clinical next generation sequencing to identify actionable aberrations in a phase I program. <i>Oncotarget</i> , 2015, 6, 20099-20110.	1.9	42
104	Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. <i>Cancer</i> , 2013, 119, 1593-1601.	4.1	187
105	Sentinel Lymph Node Biopsy in Melanoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 185-191.	2.0	28
106	ONCOS-102: A Step Forward or Sideways?. <i>Clinical Cancer Research</i> , 0, , OF1-OF2.	7.2	0
107	Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis. <i>Annals of Surgical Oncology</i> , 0, , .	1.9	0
108	Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting. <i>Clinical Cancer Research</i> , 0, , OF1-OF16.	7.2	2

#	ARTICLE	IF	CITATIONS
109	Targeting IL-17A to combat immune-related adverse events. Nature Cancer, 0, , .	12.1	0